Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
Trial Parameters
Brief Summary
The purpose of this study is to analyze esophageal cancer patients who underwent neoadjuvant immunotherapy with chemotherapy followed by esophagectomy to determine whether additional adjuvant therapy is associated with improved survival outcomes.
Eligibility Criteria
Inclusion Criteria: 1. The patient volunteers to participate in the study, signs a consent form, has good compliance, and obeys the follow-up, and is willing and able to follow the protocol during the study; 2. Histologically-confirmed squamous cell carcinoma; tumors of the esophagus are located in the thoracic cavity; 3. Have not received systemic and local treatment for esophageal cancer; 4. Pre-treatment staging as cT1b-3N1-3M0 or T3N0M0, American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) 8th edition; 5. Male or female, aged ≥18 and ≤75 years; 6. The Eastern Cooperative Oncology Group (ECOG) performance status (PS) score is 0 -1; 7. R0 resection is expected; 8. Adequate cardiac function. All patients should perform electrocardiogram (ECG), and those with a cardiac history or ECG abnormality should perform echocardiography with the left ventricular ejection fraction \>50%; 9. Adequate respiratory function with forced expiratory volume in 1 second